or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)

DRUG2 trials

Sponsors

Pfizer

Conditions

Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Phase 3

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

CompletedNCT01595438

PfizerComplicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Start: 2012-10-31End: 2014-08-31Updated: 2017-09-06

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

CompletedNCT01599806

PfizerComplicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Start: 2012-10-31End: 2014-08-31Updated: 2017-09-06

Related Papers

Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme

Journal of Antimicrobial Chemotherapy2023-09-1316 citations

Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.

2021-08-1021 citations

Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.

2020-08-0115 citations

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.

2018-09-0161 citations

Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Clinical Infectious Diseases2016-06-16338 citations

Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects

Pharmacology Research & Perspectives2015-08-2542 citations